GLP-1 drugs are now friendlier to needle-phobes. But do the pills still work?

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...

CVS Health will restore Eli Lilly’s weight-loss injection Zepbound to its list of covered drugs and also add the drugmaker’s ...

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss.

Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects.

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug ...

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some ...

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of effectiveness, side effects, average costs and the best online weight loss ...

FDA approvals of Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo have introduced needle-free obesity treatments, offering ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they contain the same active ingredient, tirzepatide, and may affect blood ...